On December 13, 2022, the COVID-19 vaccine developer Moderna and pharmaceutical company Merck announced a progressive advancement in forming vaccination for melanoma, known as one of the most fatal types of skin cancer.
Moderna is collaborating with Merck to study and create a feasible melanoma vaccine among patients who had surgery for their cancer. The study combines an mRNA vaccine strategy and a drug to expedite the immune system and bring favorable results for melanoma patients.
With the vaccine and Merck's immunotherapy Keytruda, the team saw a notable difference in the patient's survival rate. “We are very excited, we are moving very quickly with Merck onto phase 3 for this study,” shared Moderna CEO Stephane Bancel with CNBC. Phase 3 is typically the most costly stage of research before the drug gets officially approved.
/Passle/60211dc9e5416a0c14bc63d4/SearchServiceImages/2026-07-28-19-51-35-599-6a6908473c54dccaed67d767.jpg)
The global issues we face are challenging and interconnected. They can seem insurmountable. But if you know where to look, co-operation, positive change and hope are all around us. Build Beyond Even Better is a project that recognises the progress being made, and the amazing people who are making a difference. Share your own hopes, pledges and projects with #BBEB, or become a contributor.
Please read our BBEB Charter PDF.
/Passle/60211dc9e5416a0c14bc63d4/SearchServiceImages/2026-07-20-15-47-13-888-6a5e43013455c3b50efccfd9.jpg)
/Passle/60211dc9e5416a0c14bc63d4/SearchServiceImages/2026-07-16-13-43-41-817-6a58e00dae32eb629c4bd761.jpg)
/Passle/60211dc9e5416a0c14bc63d4/SearchServiceImages/2026-07-27-16-31-43-655-6a6787ef103ad9461a4b75f5.jpg)
